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Abstract
ERBB2 amplification is a therapeutic target in 5% of patients with RAS wild-type metastatic colorectal
cancer. At 6.7 years of follow-up, therapy with trastuzumab and lapatinib combination resulted in 28%
objective response rate with 1 patient still in complete response, median 4.7 months progression-free
survival, and 10.0 months overall survival. Progression in the central nervous system occurred in 19% of
patients.
Background: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has
been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or tras-
tuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A trial) at
6.7 years (82 months) follow-up and focus on central nervous system (CNS) recurrences. Patients and Methods:
Patients had histologically confirmed KRAS exon 2 (codons 12 and 13) wild-type and HER2-positive mCRC. HER2
positivity was assessed by immunohistochemistry and in situ hybridization HERACLES diagnostic criteria. Patients
were treated with intravenous trastuzumab 4 mg/kg loading dose, then 2 mg/kg once per week, and oral lapatinib
1000 mg per day until disease progression or toxicity. Patients who presented with symptoms or signs of CNS disease
received brain computed tomography scan or magnetic resonance imaging. Results: A total of 35 patients received
trastuzumab and lapatinib and 32 were evaluable for response. One patient (3%) achieved complete response (CR), 8
(25%) partial response, and 13 (41%) stable disease. Therefore, response rate was 28%. Median progression-free
survival was 4.7 months (95% confidence interval [CI] 3.7e6.1). Median overall survival was 10.0 months (95% CI
7.9e15.8). One patient achieved sustained CR still maintained at 7 years of follow-up. Progression in the centralF.T. and A.S.-B. contributed equally as first authors.
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nervous system (CNS) occurred in 6 (19%) of 32 patients. Conclusions: Long-term (6.7 years) follow-up analysis of
HERACLES-A supports using of trastuzumab and lapatinib as treatment reference for KRAS wild-type, chemo-
refractory HER2-positive mCRC. In this subset of patients, prolongation of survival is accompanied by CNS re-
currences that will require diagnostic and therapeutic attention in future studies.Clinicaltrials. Gov identifier:
NCT 03225937.
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Median number of prior lines (range) 5 (2-11)
Patients with > 3 prior lines 24 (75)
Prior cetuximab or panitumumab 32 (100)
aLocated in cecum, ascending colon, liver flexure, and transverse colon.
bLocated in splenic flexure, descending colon, and sigmoid colon.Introduction
In metastatic colorectal cancer (mCRC), ERBB2 amplification
occurs in 5% of RAS wild-type cases1 and in the 2019 National
Comprehensive Cancer Network (NCCN) Treatment Guidelines
for Colon Cancer2 this molecular alteration has been recognized as a
valuable therapeutic target with 2 HER2-directed drug combina-
tions: trastuzumab and lapatinib3 or trastuzumab and pertuzumab.4
With the former regimen, we recently reported briefly the original
finding of a high rate of central nervous system (CNS) recurrences
in this patient population.5 In the present article we detail in full the
long-term clinical results of the pivotal HERACLES-A trial of
trastuzumab and lapatinib in an extended population of 32 patients
with mCRC at a follow-up of 6.7 years with an expanded focus on
timing, characteristics, and treatment of CNS recurrences.
Patients and Methods
Patients and Treatment
Patients were treated in the HERACLES-A trial3 and had a
histologically confirmed diagnosis of mCRC with KRAS exon 2
(codons 12 and 13) wild-type status and HER2 positivity, as
defined by the CRC-specific HERACLES diagnostic criteria (tu-
mors with 3þ HER2 score in >50% of cells by immunohisto-
chemistry or with 2þ HER2 score and a HER2:CEP17 ratio >2 in
>50% of cells by fluorescence in situ hybridization [FISH]).6 Pa-
tients were treated with trastuzumab, intravenously at 4 mg/kg
loading dose, then at 2 mg/kg once per week, and lapatinib, orally at
1000 mg per day in 21-day treatment cycles (ie, 1 weekly trastu-
zumab dose and 1 daily lapatinib dose). Inclusion/exclusion criteria,
screening phase, treatment/dose schedules, and tumor assessments
were as previously described.3
Follow-up and CNS Relapse
Tumor assessmentswere done at baseline and every 8weeks thereafter
until progression. Follow-up for overall survival (OS)was updated to 6.7
years after study treatment started. Assessments weremade for death and
for CNS recurrence. Patients who presented with symptoms or signs of
CNS disease received brain computed tomography (CT) scan with
intravenous (I.V.) contrast and, if clinically indicated, magnetic reso-
nance imaging with I.V. contrast. HERACLES-A trial protocol did not
have specific indications for CNS relapses and all cases were diagnosed
and treated as per best clinical practice.
Results
We screened and enrolled patients with mCRC between August
27, 2012, and March 15, 2016. Screening details were previouslydescribed.3 A total of 35 patients were enrolled and treated with
trastuzumab and lapatinib (27 in the trial phase, 8 in an extension
cohort). Of these, 3 were not evaluable for response (concomitant
RAS mutation 2 cases, absence of target lesions assessable by
RECIST, 1 case [Supplemental Figure 1 in the online version]). The
characteristics of the 32 fully evaluable patients are displayed in
Table 1. At the time of the end of the study (May 15, 2019), the
follow-up was 82 months (6.7 years). Of the 32 patients, one had a
complete and 8 (25%) had a partial response, for a total of 9 (28%)
patients achieving objective response rate (ORR). Stable disease
(SD) was observed in 13 (41%) patients and lasted 4 months in 9.
Overall, disease control was achieved in 22 patients (69%),
lasting 4 months in 18 (56%). Table 2 shows treatment-related
adverse events according to Common Terminology Criteria for
Adverse (CTCAE) events that occurred in at least 5% of patients or
all that were grade 3 or worse. Three patients underwent the
treatment for more than 1 year: of them, only 1 patient displayed
fatigue grade 3 and an asymptomatic decrease in left ventricular
ejection fraction grade 3 that improved and reversed to grade 1 after
temporary suspension.Clinical Colorectal Cancer December 2020 - 257
Table 2 Adverse Events
Adverse Events Grades 1-2 Grade 3
Gastrointestinal
Diarrhea 26 (81) 1 (3)




Rash 17 (53) 1 (3)
Dry skin 8 (25)




Metabolic and nutritional disorders




Hand-foot syndrome 2 (6)
Blood bilirubin increase 1 (3)
Decrease in left ventricular ejection fraction 2 (6)
Data are n (%). Treatment-related adverse events are reported if they occurred in at least 5% of
patients or were of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or worse.
All 32 patients were included in the analysis. No grade 4 or 5 adverse events occurred.
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258 -Median progression-free survival (PFS) was 4.7 months (95%
confidence interval [CI] 3.7e6.1). At 7 years after treatment initi-
ation, 1 of 32 patients is still in complete remission, and thus
potentially cured. Median OS was 10.0 months (95% CI
7.9e15.8) with the latter patient alive censored at the time of data
cutoff. Figure 1 shows a swimmer plot of PFS and OS.
CNS Relapses
Symptomatic disease progression in the CNS occurred in 6
(19%) of 32 evaluable patients. The characteristics of these patients
and their CNS progression and treatments are reported in Table 3.
Five of 6 patients achieved a clinical benefit from the anti-HER2
treatment (2 with partial response [PR] and 3 with SD). Figure 2
shows the treatment history of this particular cohort of patients
who developed brain progression. Four patients progressed while on
anti-HER treatment and median time to progression in the CNS
was 7.9 months. Exclusive brain progression occurred in 3 patients,
whereas in the other 3 patients the progression was generalized.
Median OS was 11.4 months. Treatments consisted of stereotactic
brain radiation therapy (n ¼ 2) and neurosurgery excision (n ¼ 1).
Because of poor performance status, 2 remaining patients received
best supportive care and 1 was lost to follow-up. In the patient who
underwent neurosurgery for a cerebellum secondary localization,
manifested 11.5 months after treatment initiation (UPN 121003),
the CNS metastases maintained HER2-positivity (immunohisto-
chemistry [IHC] 3þ) and status of KRAS and BRAF wild-type as
compared with a metachronous lung metastasis, analyzed before
HER2-targeted treatment, and the primary tumor (Figure 3). WeClinical Colorectal Cancer December 2020additionally did not find in the CNS lesion any mutations of
ERBB2.
Discussion
This long-term follow-up analysis of the HERACLES-A trial
demonstrates that pharmacological double HER2 blockade with
trastuzumab and lapatinib, as foreseen by preclinical models,7,8
constitutes a therapeutic reference for the treatment of mCRC
where this biomarker is present.6 The value of ERBB2 amplification
as a therapeutic target in mCRC has been confirmed in the
MyPathway trial4 in which the combination of trastuzumab and
pertuzumab was used, and both regimens achieve level 2 OncoKB
designation (https://www.oncokb.org) and inclusion in the NCCN
Guidelines for colon cancer. Further, the more recently presented
MOUNTAINEER trial with trastuzumab and tucatinib and
DESTINY-CRC01 with the antibody-drug conjugate trastuzumab
deruxtecan showed the potential for improvement of these results
with newer HER2-targeted agents.9,10
In the present HERACLES-A extended population of 32 patients
we observed an ORR of 28% (95% CI 14%e47%) and a median
PFS of 4.7 months. These results are achieved in a heavily pretreated
population in which standard therapeutic options such as regor-
afenib or trifluridine-tipiracil do not provide meaningful ORR.11,12
Interestingly, we documented a sustained complete response (CR)
still maintained at 7 years of follow-up (Supplemental Figure 2 in
the online version). These results confirm that the benefit obtained
by targeting oncogenic addictive products such as HER2 can lead to
unprecedented clinical benefit and survival. HERACLES-A data
presented here compare indeed favorably with the other 2 thera-
peutic strategies for biomarker-defined mCRC populations, such as
triple BRAF-directed therapy13 and microsatellite instability-
confined treatment with immune checkpoint inhibitors.14 In this
regard, from a clinical standpoint, HER2-targeted treatment seems
to reconcile the strengths of targeted oncology against oncogenes
(rapid and deep induction of tumor shrinkage) with those of
immunotherapy (durability of responses and the potential for cure).
Treatment-prolonged survival in this cohort of patients with
chemorefractory HER2-positive mCRC resulted in an unexpectedly
high occurrence of CNS metastases in approximately one-fifth of
patients. This incidence rate is 4 times higher than usually reported
in mCRC.15 Several considerations can be made to explain this
finding: a potential biological tropism toward CNS of ERBB2-
amplified cells; a limitation of trastuzumab and lapatinib to cross the
bloodebrain barrier (BBB); or the increased likelihood in patients
with long survival outcomes of developing involvement of rarer
anatomic sites than observed in the general population of mCRC.
The hypothesis that ERBB2 amplification drives a higher pro-
pensity to spread to CNS has been already documented for
breast16,17 and gastric cancer.18,19
Approximately only 1% to 4% of patients with mCRC are re-
ported to develop CNS metastases.20,21 However, limited data are
available about the correlation between ERBB2 amplification and
tendency to CNS metastasis. Tan et al.15 recently pointed out that
20% of 40 patients with mCRC developing CNS metastases were
characterized by ERBB2 amplification in the primary tumor. In
another recent publication,22 14 patients with mCRC undergoing
craniotomy because of CNS metastasis were tested by IHC and
Figure 1 Swimmer Plot Regarding Progression-free Survival (PFS) and Overall Survival (OS) of HER2-Positive Patients Treated With
Trastuzumab and Lapatinib. Green Bars Represent Patients Who Achieved Complete Response (CR) and Partial Response
(PR), whereas Yellow and Red Bars Indicate Stable (SD) and Progressive Disease (PD), Respectively. Bars With Black Line
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Abbreviations: CNS PD ¼ progression of disease in the CNS; Pts ¼ patients.
Federica Tosi et alFISH for ERBB2 amplification and 3 of them (21%) resulted
positive with 100% concordance with primary tumor. These data,
together with present findings from a selected population of HER2-
positive patients with mCRC, support the hypothesis that ERBB2Table 3 Clinical Characteristics and Treatments of Patients Showin


















121009 NA 4.2 On-treatment 0.4
121027 supratentorial lesions 2.1 On-treatment 0.1
Abbreviations: CNS ¼ central nervous system; NA ¼ not available; ORR ¼ objective response rate; O
response; SD ¼ stable disease.
aThis patient developed brain metastases after treatment with trastuzumab þ lapatinib and T-DM1
bPatient remained on HERACLES-A treatment during brain radiotherapy.amplification, as also DNA damage response pathway defects,23 is a
mechanism that drives higher propensity to spread to CNS.
Another explanation for the high incidence of CNS progression












PR None 35.3 4.8
PR None 13.9 0.3








S ¼ overall survival; PD ¼ progressive disease; PFS ¼ progression-free survival; PR ¼ partial
given as sequential rescue treatment within the HERACLES-RESCUE study.
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Abbreviations: CNS PD ¼ disease progression to CNS; OSH ¼ overall survival following HERACLES-A treatment; PFS1 ¼ progression-free survival with first-liine treatment; PFS2 ¼ PFS with second-
line treatment; PFS3 ¼ PFS with third-line treatment; PFS4 ¼ PFS with fourth-line treatment; PFSH ¼ PFS with trastuzumab and lapatinib (HERACLES-A).
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260 -therapies, particularly trastuzumab.24 Indeed, pharmacokinetics
evidence obtained from phase I trials involving anti-HER2 drugs
demonstrated different capability to bypass the BBB due to their
dimension (ie, molecular mass >450 kDa) or their hydrophilic
nature.25,26 Trastuzumab, when administered as an I.V. infusion,
poorly crosses the BBB. In radiotherapy-naïve patients, trastuzumab
concentrations have been reported to be 420-fold lower in cere-
brospinal fluid (CSF) than in serum.27 Even after radiotherapy, the
blood/CFS trastuzumab concentration remains low (1:49).27
Lapatinib is a small molecule reversible tyrosine kinase inhibitor
designed to target both HER1 (epidermal growth factor receptor)
and HER2. Being a small molecule (molecular weight <1 kDa),
lapatinib should be able to cross the BBB and reach CNS deposits.28
In a preclinical study on healthy animals, however, the ability of
lapatinib to cross the BBB was limited due to efflux transporter P-
glycoprotein,29 a selective gatekeeper of the BBB and thus a primary
obstacle to drug delivery into the brain. Several clinical trials eval-
uated the CNS efficacy of lapatinib obtaining conflicting
results.30,31
Finally, another reason explaining why HER2-positive tumors
seem to develop more CNS metastases is the prolonged survival
obtained thanks to the anti-HER2 treatment itself. This gain in
survival might indeed allow the unmasking of brain deposits
otherwise clinically silent.32,33 In HERACLES-A, we observed a
median OS of 10.0 months, with 1 patient still in CR after 7 years
and this survival time from the initiation of HER2-targeted treat-
ment must be added to the time elapsed since the diagnosis of
metastatic disease, which was considerable in HERACLES-A (pa-
tients had received a median of 4 previous treatment lines before
enrollment). Indeed, the median OS for the entire cohort of 32
patients since the diagnosis of stage IV is 42.3 months, higher than
expected (Supplemental Table 1 in the online version).
Our analysis regarding CNS involvement in HERACLES-A has
some limitations. First, we did not perform a brain imaging on theClinical Colorectal Cancer December 2020entire cohort of HER2-positive patients with mCRC but only in
symptomatic patients, so that we could not exclude an even higher
incidence in this population. Second, we compared our cohort with
historical data on incidence of brain metastases in patients with
mCRC patients and not with patients with HER2-positive tumors
who did not receive trastuzumab/lapatinib or patients with HER2-
negative mCRC.
Altogether our findings support the hypothesis that, in HER2-
positive patients with mCRC treated with trastuzumab and lapati-
nib, CNS represents a sanctuary of disease progression. Based on
this, we recommend to include brain imaging for staging and tumor
assessment in these patients.
Conclusion
In conclusion, updated analysis of HERACLES-A trial confirms
trastuzumab and lapatinib as a HER2-directed combination of
reference for KRAS wild-type, chemorefractory HER2-positive
mCRC. We also document that CNS represents a sanctuary site
of relapse, a finding that calls for inclusion of brain imaging for
staging and tumor assessment in this patient population. Further
studies will shed light on the mechanisms underlying this tropism
and will investigate the potential of new-generation tyrosine kinase
inhibitors with capability of CNS penetration and possibly clinical
activity.9,34-36
Clinical Practice Points
 HERACLES-A pivotal multicenter phase-II trial demonstrated
trastuzumab and lapatinib as an active combination in treating
HER2-positive chemorefractory mCRC.
 These results document that the benefit obtained by targeting
oncogenic addictive products such as HER2 can lead to un-
precedented clinical benefit and survival. We report a sustained
CR maintained at 7 years of follow-up. Interestingly, a high
Figure 3 Representative Patient 121003 Showing Progression of a Metastatic Lesion in the Cerebellum Retaining ERBB2 Amplification
in HERACLES-A Trial. (A) Representative Computed Tomography (CT) Scan of the Lung (Left) and Cerebellum Metastasis
(Right) Observed in Patient 121003 after 13.6 months of Treatment With Trastuzumab and Lapatinib. (B) Corresponding
Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) Analyses of Lung (Left) and Cerebellum
Metastasis Obtained Through Surgical Excision (Right), Showing Maintenance of ERBB2 Amplification. Parallel Mutational
Analysis Demonstrated KRAS and BRAF Wild-type in Both Specimens. Original Magnification for Hematoxylin-Eosin and
HER2 Immunohistochemistry (Inner Left Picture) Staining Pictures is 3200 (Scale bar: 100 mm) and Original Magnification
for FISH Pictures (Inner Right Picture) is 3630 (Scale bar: 20 mm)
Federica Tosi et alprevalence of CNS recurrences indicated this site as a sanctuary
of relapse in this subset of HER2-positive patients with mCRC.
 Trastuzumab and lapatinib combination was confirmed as a
reference therapeutic option for HER2-positive mCRC in
advanced line. In this population, CNS represents a sanctuary of
disease progression, therefore we recommend to include brain
imaging for staging and tumor assessment.Acknowledgments
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Abbreviation: OS ¼ overall survival.
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